Clinical Trial

[Subject recruitment] A open-label, dose-escalation Phase I trial of PA3-17 injection in adult patients with CD7-positive relapsed/refractory lymphoid hematologic malignancies


CD7 is a transmembrane glycoprotein expressed on the surface membranes of T and NK cells and their precursor cells to stimulate cell activation. We have shown in pre-clinical studies that the cell-based immunotherapy targeting CD7 bio-drug (CD7-CAR-T) has excellent efficacies in the treatment of relapsed/refractory acute T lymphoblastic leukemia and lymphoma. The bio-drug has been approved by the National Medical Products Administration (China) (Reference number: CXSL2101087) for phase I clinical trial and met the ethical standards of clinical trials after reviewed by the ethics committee. The clinical trials are currently being carried out in 5 hospitals in China.


The major inclusion criteria

(1) Aged 18 to 70 years old (inclusive), male or female;

(2) Subjects diagnosed with malignant lymphoma according to WHO 2016 criteria:

T-cell acute lymphoblastic leukemia/lymphoma (including early pre-T-cell lymphoblastic leukemia) with priority,


Subjects with relapsed/refractory acute T-lymphoblastic leukemia/lymphoma (including early-stage pre-T-lymphoblastic leukemia) who have failed standard therapies or lack of effective therapies, and meet any of the following criteria:

  • Have not achieved remission after at least two courses of standard induction chemotherapies.

  • Relapsed in the early stage (<12 months) after complete remission; or relapsed in the late stage (≥12 months) after complete remission and did not achieve remission with one more course of standard induction chemotherapy.

  • Have not achieved remission after two or more courses of chemotherapies.

  • Relapsed after hematopoietic stem cell transplantation.

(3) Subjects diagnosed with lymphoid hematologic malignancies and screened CD7-positive by flow cytometry and/or immunohistochemistry, with the positive rate of tumor cells ≥ 30%.

(4) CD-7-positive lymphoid hematologic malignancies with bone marrow and/or peripheral blood involvement, with immunophenotype of CD4 and CD8 double-negative on tumor cell membranes determined by flow cytometry.


Please contact us for more inclusion criteria.

Center Number




Perking University People’s Hospital

Ying chen



The First Affiliated Hospital of Zhengzhou University

Jianhang Wei



Union Hospital Tongji Medical College Huazhong University of Science and Technology

Duanyang Shao



Hematology Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences)

Jian Li



The First Affiliated Hospital of Zhejiang University

Yamei Qin